Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep;17(9):638-45.

Surface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy

Maryam Daram  1 , Ghodratollah Montazeri  2 , Hadi Karimzadeh  1 , Reza Malekzadeh  2 , Mahmood Mahmoodi  3 , Zahra Goodarzi  1 , Hossein Keyvani  4 , Shahram Mirmomen  5 , Seyed Moayed Alavian  6 , Michael Roggendorf  7 , Seyed Mohammad Jazayeri  1
Affiliations

Surface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy

Maryam Daram et al. Iran J Basic Med Sci. 2014 Sep.

Abstract

Objective s: The aim of this study was to determine the correlation between vaccine therapy and appearance of mutations in hepatitis B surface antigen (HBsAg)-positive chronic hepatitis B virus (HBV) patients.

Materials and methods: 16 patients received the HBV vaccine and another 16 individuals from the control group did not. The surface gene was amplified and directly sequenced from samples prior to vaccination and six months after the third dose.

Results: Only one patient lost HBsAg. 48 and 44 amino acid mutations were found before and after vaccine therapy in the vaccine group respectively, 51 of which (55.4%) occurred in immune epitopes: 5 were in B cell, 21 in T helper (Th), and 25 in cytotoxic T-lymphocyte (CTL) epitopes. In the control group, 35 and 41 amino acid substitutions were found before and after therapy, respectively. 32 (42%) of 76 amino acid changes occurred within immune epitopes. There were no differences in age, gender, and duration of chronicity in both patient and control groups in terms of the frequency and the patterns of mutations.

Conclusion: In chronic carriers who already had HBsAg variants selected by the host-immune response, any immune stimulation by the vaccine had no effect on the chronic state of these patients or selected any remarkable escape mutants. Newer strategies should be considered based on third generation or the use of DNA vaccines or new adjuvants.

Keywords: HBsAg mutants; Hepatitis B immune epitopes; Hepatitis B vaccine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Diagram shows percentage of mutations frequency in recipient vaccine and control group at the same time
Figure 2.
Figure 2.
Position of amino acid and number of mutations at immune epitope in reciipien vaccine group before and after therapy
Figure 3.
Figure 3.
Position of amino acid and numberof mutations at immuno epitopes in control group before and after therapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Fontaine H, Thiers V, Pol S. Hepatitis B virus genotypic resistance to lamivudine. Ann Intern Med. 1999;131:716–717. - PubMed
    1. Zoulim F, Trepo C. New antiviral agents for the therapy of chronic hepatitis B virus infection. Intervirology . 1999;42:125–144. - PubMed
    1. Bidgoli SA, Daryani NE, Motamedi M, Miri A, Poorsamimi P. Evaluation of possible risk factors of lamivudine resistance in chronic hepatitis b patients: a retrospective study in Iran. Hepat Mon. 2009; 9:171–179.
    1. Pol S, Driss F, Michel ML, Nalpas B, Berthelot P, Brechot C. Specific vaccine therapy in chronic hepatitis B infection. Lancet . 1994; 344:342. - PubMed
    1. Pol S, Michel ML, Brechot C. Immune therapy of hepatitis B virus chronic infection. Hepatology . 2000; 31:548–549. - PubMed

LinkOut - more resources